Table 1.
Current clinical trials using oncolytic HSV (as listed on ClinicalTrials.gov, accessed April 2019).
| HSV | Study | Identifier | Phase |
|---|---|---|---|
| OH2 | Phase I Study of OH2 Injection, an Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Malignant Solid Tumors | NCT03866525 | 1 |
| rRp450 | rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors | NCT01071941 | 1 |
| Orien X010 |
Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010), Standard Injection in Tumor, Treatment Scheme Failed, M1c IV Period, Malignant Melanoma Spread to the Liver, Open I-c Phase of Clinical Trial | NCT03048253 | 1c |
| M032 | A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients With Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma | NCT02062827 | 1 |
| C134 | A Phase I Trial of IRS-1 HSV C134 Administered Intratumorally in Patients With Recurrent Malignant Glioma | NCT03657576 | 1 |
| G207 | Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | NCT03911388 | 1 |
| G207 | Phase I Clinical Trial of HSV G207 Alone or With a Single Radiation Dose in Children With Recurrent Supratentorial Brain Tumors | NCT02457845 | 1 |
| T-VEC | A Phase I, Open Label, Single Arm, Single Centre Study to Evaluate Mechanism of Action of Talimogene Laherparepvec (T-VEC) in Locally Advanced Non-melanoma Skin Cancer | NCT03458117 | 1 |
| T-VEC | A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | NCT02779855 | 1/2 |
| T-VEC | A Phase II Study Using Talimogene Laherparepvec as a Single Agent for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence | NCT02658812 | 2 |
| T-VEC | A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors | NCT02978625 | 2 |
| T-VEC | A Phase 1b Study of Talimogene Laherparepvec (T-VEC) in Combination With Paclitaxel or Endocrine Therapy in Patients With Metastatic, Unresectable, or Locoregionally Recurrent HER2-Negative Breast Cancer With Evidence of Injectable Disease in the Locoregional Area | NCT03554044 | 1b |
| T-VEC | A Phase II Study of Combining Talimogene Laherparepvec T-VEC (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy | NCT02965716 | 2 |
| T-VEC | A Phase I Study of Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum | NCT03300544 | 1 |